1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 October 2018 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.516
|
208
|
||
£14.516
|
226
|
||
£14.516
|
792
|
||
£14.516
|
207
|
||
£14.516
|
226
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
1659
£14.516
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 October 2018 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.516
|
141
|
||
£14.516
|
117
|
||
£14.516
|
167
|
||
£14.516
|
117
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
543
£14.516
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S Dingemans
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 October 2018 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.516
|
274
|
||
£14.516
|
205
|
||
£14.516
|
560
|
||
£14.516
|
274
|
||
£14.516
|
205
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
1518
£14.516
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 October 2018 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.516
|
101
|
||
£14.516
|
74
|
||
£14.516
|
88
|
||
£14.516
|
101
|
||
£14.516
|
74
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
438
£14.516
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of thetransaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 October 2018 on ADSs held in the Company's
Deferred Annual Bonus Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$38.47
|
84
|
||
$38.47
|
82
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
166
$38.47
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr L Miels
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 October 2018 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.516
|
159
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
n/a (single transaction)
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 October 2018 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.516
|
129
|
||
£14.516
|
93
|
||
£14.516
|
162
|
||
£14.516
|
93
|
||
£14.516
|
129
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
606
£14.516
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms K Terrell
|
|
b)
|
Position/status
|
Chief Digital & Technology Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of thetransaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 October 2018 on ADSs held in the Company's
Deferred Annual Bonus Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$38.47
|
28
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
n/a (single transaction)
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 October 2018 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.516
|
189
|
||
£14.516
|
141
|
||
£14.516
|
177
|
||
£14.516
|
189
|
||
£14.516
|
141
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
837
£14.516
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 October 2018 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.516
|
115
|
||
£14.516
|
88
|
||
£14.516
|
110
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
313
£14.516
|
|
e)
|
Date
of thetransaction
|
2018-10-12
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: October
17, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|